HR 2641 · 115th Congress 2017–2019, ended

Promoting Life-Saving New Therapies for Neonates Act of 2017

Latest action · May 26, 2017 Referred to the Subcommittee on Health.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedMay 24, 2017
  2. Passed HouseNot reached
  3. Passed SenateNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Promoting Life-Saving New Therapies for Neonates Act of 2017

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to award the sponsor of a new drug or biological product for the treatment of newborns a neonatal drug exclusivity voucher upon approval of the medication. A neonatal drug exclusivity voucher is a transferable voucher for a one-year extension of all existing patents and marketing exclusivities for a brand name medication. For a sponsor to be eligible for a voucher, the new medication must: (1) treat a condition identified in the Priority List of Critical Needs for Neonates required under this bill, and (2) have been studied in newborns.

A voucher may be revoked if the new medication is not marketed in the United States within one year of approval.

A voucher may not be used: (1) to extend the marketing exclusivity period for a drug for which the FDA requires an assessment of the safety and effectiveness in newborns, or (2) on the same product as a priority review voucher.

A sponsor intending to use a voucher must notify the FDA at least 15 months before the expiration of the patents or exclusivity to be extended.

The Government Accountability Office must study the effectiveness of this voucher program.

Cosponsors 37

Members who signed on, in the order they did. Signatures ran from May 24, 2017 to Dec 18, 2017; 1 is an original cosponsor, there from the day it was introduced.

SeatCosponsorSigned on
D-NMBen Ray LujánOriginalMay 24, 2017
D-NJBill Pascrell, Jr.Jun 7, 2017
D-CAGrace F. NapolitanoJun 7, 2017
D-CAJohn GaramendiJun 7, 2017
D-WADerek KilmerJun 13, 2017
D-VAGerald E. ConnollyJun 13, 2017
D-NYKathleen M. RiceJun 13, 2017
D-DELisa Blunt RochesterJun 13, 2017
D-CAMark DeSaulnierJun 13, 2017
D-CAScott H. PetersJun 13, 2017
D-MASeth MoultonJun 13, 2017
D-CATony CárdenasJun 13, 2017
R-KYBrett GuthrieJun 21, 2017
R-MEBruce PoliquinJun 21, 2017
R-NJLeonard LanceJun 21, 2017

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseEnergy and Commerce Committee
Referred May 24, 2017
Health Subcommittee
Referred May 26, 2017

Actions 3

Everything that happened, newest first.

  1. May 26, 2017Referred to the Subcommittee on Health.
  2. May 24, 2017Introduced in House
  3. May 24, 2017Referred to the House Committee on Energy and Commerce.

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Constitutional authority

Congress has the power to enact this legislation pursuant to the following: Article 1, Section 8, Clause 18 of the Constitution, which states ``To make all Laws which shall be necessary and proper in the Government of the United States or in any Department or Officer thereof.''

The sponsor’s statement, as printed in the Congressional Record, vol. 163, no. 90, May 24, 2017, page H4570.

Related bills 1

Companion bills and other measures the record links to this one.

BillTitleRelationshipLatest action
HR 5182Promoting Life-Saving New Therapies for Neonates Act of 2016Reintroduction ofMay 13, 2016

Titles 2

Every title it has carried, official and short, at each stage.

Official Title as Introduced
To promote the development of safe drugs for neonates.
Short Titles as Introduced
Promoting Life-Saving New Therapies for Neonates Act of 2017

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. May 24, 2017Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.